Expertise in
20
conditions

Dr. Beth A. Christian

Hematology | Hematology Oncology
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Beth Christian is a Hematologist and a Hematologist Oncology provider in Dublin, Ohio. Dr. Christian is highly rated in 20 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Christian is currently accepting new patients.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Procedure, Drug
Study Drugs: Ibrutinib, Lenalidomide
Study Phase: Phase 1
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Obinutuzumab, Venetoclax
Study Phase: Phase 1
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Acalabrutinib, Rituximab, Lenalidomide
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 1/Phase 2
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drug: TRPH-222
Study Phase: Phase 1
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Lenalidomide
Study Phase: Phase 1
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

59 Total Publications

Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results.
Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results.
Journal: Blood advances
Published: March 13, 2025
Similar Doctors
Expertise in
44
conditions
Dr. Spero R. Cataland
Hematology | Oncology | Hematology Oncology
Expertise in
44
conditions
Dr. Spero R. Cataland
Hematology | Oncology | Hematology Oncology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
 (8.2 mi)
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Spero Cataland is a Hematologist and an Oncologist in Columbus, Ohio. Dr. Cataland is highly rated in 44 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy. Dr. Cataland is currently accepting new patients.

Michael R. Grever
Expertise in
9
conditions
Dr. Michael R. Grever
Hematology | Hematology Oncology
Expertise in
9
conditions
Dr. Michael R. Grever
Hematology | Hematology Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (0.1 mi)
614-889-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Grever is a Hematologist and a Hematologist Oncology provider in Dublin, Ohio. Dr. Grever is highly rated in 9 conditions, according to our data. His top areas of expertise are Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, and Splenectomy. Dr. Grever is currently accepting new patients.

Kami J. Maddocks
Expertise in
22
conditions
Dr. Kami J. Maddocks
Hematology
Expertise in
22
conditions
Dr. Kami J. Maddocks
Hematology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (0.1 mi)
614-889-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kami Maddocks is a Hematologist in Dublin, Ohio. Dr. Maddocks is highly rated in 22 conditions, according to our data. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maddocks is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Christian's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile